China's first SARS-CoV-2 neutralizing antibody enters clinical trials
Junshi Biosciences cites Lonza’s GS Xceed gene expression system as a critical enabler for the program.
Lonza and Junshi Biosciences have announced that the first healthy volunteer has been dosed in a Phase I clinical study of JS016 at Huashan Hospital affiliated to Fudan University in China.
JS016 is the first SARS-CoV-2 neutralizing antibody that has entered clinical trials in China and is produced using Lonza’s GS Xceed gene expression system. This follows on from a successful launch of the first PD-1-targeting antibody using GS Xceed last year.
At the start of the COVID-19 outbreak, Junshi Biosciences rapidly launched the R&D program focused on neutralizing antibodies using Lonza's GS Xceed expression system. Within 2 months, the company had completed investigational new drug (IND) enabling preclinical studies, process development and production for GLP toxicity studies, as well as the GMP production of clinical material.
Junshi Biosciences is collaborating with Eli Lilly to co-develop JS016 globally, with Junshi leading clinical development in Greater China and Lilly leading clinical development in the rest of the world.
Lonza’s expression technology platform includes host cell lines, vectors, and access to optimized media and feeds, as well as comprehensive methods and processes. It can express a diverse range of biologic drugs and has an unparalleled track record of successfully taking programs from gene through cell line construction to commercial products.
Together with the technical and regulatory expertise, this expression system is expected to provide valuable support for the JS016 program by helping to improve cell line development timelines and improving yields.
Dr Feng Hui, Chief Operation Officer of Junshi Biosciences said: “Time to market is critical in this campaign against COVID-19. By leveraging Lonza’s GS Xceed gene expression system, Junshi is now successfully advancing JS016 into clinical stage in China. This powerful GS platform enabled us to fast-track chemistry, manufacturing and controls (CMC) development from stable cell line generation to non-GMP Tox material supply to GMP clinical manufacturing."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance